Incretin Atlas › Trials › ATTAIN-J (Japan)
ATTAIN-J (Japan)
Orforglipron · obesity
Design
- Molecule(s)
- Orforglipron
- Population
- obesity
- Official title
- A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2023-07 → 2025-06
- Participants
- 238
- Duration
- 72 weeks
- Registry
- NCT05931380
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| orforglipron 6 mg | obesity | 72 | 61 | — | −5.9 % vs −0.6 % Δ −5.3 pp | — | — | — | — | — | — | — | verified |
| orforglipron 12 mg | obesity | 72 | 57 | — | −8.7 % vs −0.6 % Δ −8.1 pp | — | — | — | — | — | — | — | verified |
| orforglipron 36 mg | obesity | 72 | 60 | — | −7.9 % vs −0.6 % Δ −7.3 pp | — | — | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- orforglipron 6 mg: Japanese adults with obesity disease (BMI 27 to <35 with ≥2 or ≥35 with ≥1 obesity-related disorder; ~25 % with T2D). Abstract only so far: treatment-regimen weight change; AE discontinuation, nausea and vomiting await the full text.
- orforglipron 12 mg: Japanese adults with obesity disease (BMI 27 to <35 with ≥2 or ≥35 with ≥1 obesity-related disorder; ~25 % with T2D). Abstract only so far: treatment-regimen weight change; AE discontinuation, nausea and vomiting await the full text.
- orforglipron 36 mg: Japanese adults with obesity disease (BMI 27 to <35 with ≥2 or ≥35 with ≥1 obesity-related disorder; ~25 % with T2D). Abstract only so far: treatment-regimen weight change; AE discontinuation, nausea and vomiting await the full text.
Verbatim quotes from the source (3)
- orforglipron 6 mg · weight_tp · Abstract, Findings
mean percentage change in bodyweight was -5·9% (95% CI -7·6 to -4·2) with orforglipron 6 mg
- orforglipron 12 mg · weight_tp · Abstract, Findings
-8·7% (-10·9 to -6·5) with 12 mg
- orforglipron 36 mg · weight_tp · Abstract, Findings
and -7·9% (-10·0 to -5·8) with 36 mg
Primary sources
- Yokote K, Yamauchi T, Shingaki T, Chin R, Oura T, Nagai Y, et al. Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2026. PMID: 42962687.
- ClinicalTrials.gov NCT05931380
How to cite this page
Medical Adviser's Group. Incretin Atlas: ATTAIN-J (Japan). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-j/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.